This session explores the challenges of treating calcified lesions during percutaneous coronary intervention (PCI). Learn how calcium can impede stent deliverability and expansion, potentially leading to thrombosis and restenosis. Discover the innovative Shockwave IVL technology, which uses sonic pressure waves to fracture calcium without harming surrounding...

Discover the power of drug-coated balloon (DCB) technology in modern PCI. Understand the mechanism of action, including antiproliferative agents, drug transfer to the vessel wall, and effective inhibitory level and duration of vessel wall retention. Learn how IVUS can guide optimal lesion preparation, and explore the...

Immerse yourself in a captivating collection of best clinical cases from AICT-AsiaPCR 2024. Witness the ingenuity and expertise of interventional cardiologists as they navigate complex scenarios, from addressing stuck prosthetic mitral valves to managing unconventional calcified lesions. Discover unique approaches, innovative solutions, and valuable lessons that...

This session explores the use of drug-coated balloons (DCB) and intracoronary imaging techniques in complex coronary interventions. It features a series of case presentations highlighting the application of technologies like near-infrared spectroscopy (NIRS), intravascular ultrasound (IVUS), and physiology-guided approaches to optimize outcomes in challenging scenarios. The...

Femoral artery pseudoaneurysm is a known complication following cardiac catheterization. Rarely, expansion of the pseudoaneurysm can occur and is often catastrophic. We describe a unique method employed by our centre to deal with such a complication.

Thanks to the contribution of a team of interventional cardiologists from around the globe, get the international perspective on Late-breaking Clinical Trials and Science released at TCT 2024 - check out the list below.

Transcatheter aortic valve implantation (TAVI) offers an effective, less invasive therapeutic alternative to surgical aortic valve replacement in patients with symptomatic, severe aortic stenosis. Although TAVI is demonstrated to be superior to medical therapy or surgery in patients who are at prohibitive or high risk for...

Yohei Ohno provides his takeaways from the results of the Evolut Low Risk trial which was presented by Michael J. Reardon during the ACC.25 in Chicago.

Jonathan Curio provides his take on the PROTECTED TAVR study which was presented by Samir R. Kapadia at TCT 2022. The aim was to evaluate whether TAVR with cerebral embolic protection would reduce the rate of clinical stroke in transfemoral TAVR.

Luigi Biasco provides his take on the clinical trial presented by John K. Forrest from Yale University School of Medicine, New Haven, Connecticut, USA during the 2023 ACC/WCC annual congress held in New Orleans, Louisiana.